MannKind Presents Positive Afrezza® Clinical Data from Type 1 Diabetes Study at 55th Annual Meeting of the EASD
September 19 2019 - 9:00AM
MannKind Corporation (NASDAQ: MNKD) announced that
data from a one-year study of Afrezza® (insulin human) Inhalation
Powder was presented at the 55th Annual Meeting of the European
Association for the Study of Diabetes (EASD) in Barcelona, Spain.
Oral Abstract 183: Technosphere Insulin Provides Better
Early Postprandial Glucose Control than Subcutaneous Rapid-Acting
Analog
MannKind investigators reported data1 from more
than 500 patients with type 1 diabetes comparing Afrezza to
rapid-acting injected insulin analog (insulin aspart) therapy to
assess glucose control, mealtime glucose changes, Afrezza dosing,
and rates of hypoglycemia over a one-year period.
Oral Abstract Presentation Highlights:
- When compared to injected insulin aspart, Afrezza provided
significantly better glucose control in the first two hours
following a standardized meal.
- Titration of Afrezza to approximately 1.5 to 2 times the unit
dose of injected insulin aspart resulted in significantly lower
post-meal glucose excursions and was associated with lower rates of
overall and level 2 hypoglycemia—an observation that was
particularly evident in the late (>2 hour) post-meal
period.
Dr. Anne Peters, Clinical Professor of Medicine
at the Keck School of Medicine at USC and Director of the USC
Westside Center for Diabetes Care noted that “the improved
post-meal glucose levels and lower rates of low blood sugars seen
in this study of individuals with type 1 diabetes support my
growing clinical experience. The presentation of these data
provides further evidence that proper dosing of Afrezza has the
potential to safely and effectively keep more patients within the
target glucose range at meal times.”
These data provide additional evidence
supporting the safe and effective use of Afrezza in type 1 diabetes
patients and offer insight into the dosing of this ultra
rapid-acting insulin as compared to a traditional rapid-acting
injected insulin analog.
About Afrezza®Available by prescription,
Afrezza® (insulin human) Inhalation Powder is a rapid-acting
inhaled insulin indicated to improve glycemic control in adult
patients with diabetes mellitus. Afrezza consists of a dry powder
formulation of human insulin delivered from a small and portable
inhaler. Administered at the beginning of a meal, Afrezza dissolves
rapidly upon inhalation to the lung and passes quickly into the
bloodstream (in less than one minute). This rapid absorption allows
Afrezza to begin reducing blood sugar levels within minutes of
administration. Afrezza is available in 4-unit, 8-unit and 12-unit
single-dose cartridges of insulin powder that can be used, as
prescribed by a health care professional, in combination with other
diabetes medications to achieve target blood sugar levels. For
Afrezza doses exceeding 12 units, patients may use a combination of
existing cartridge strengths. For more information about Afrezza,
please visit www.afrezza.com.
About MannKind CorporationMannKind Corporation
(NASDAQ:MNKD) focuses on the development and commercialization of
inhaled therapeutic products for patients with diseases such as
diabetes and pulmonary arterial hypertension. MannKind is currently
commercializing Afrezza® (insulin human) Inhalation Powder, the
Company's first FDA-approved product and the only orally inhaled
ultra rapid-acting mealtime insulin in the United States, where it
is available by prescription from pharmacies nationwide. MannKind
is headquartered in Westlake Village, California, and has a
state-of-the art manufacturing facility in Danbury, Connecticut.
The Company also employs field sales and medical representatives
across the U.S. For further information, visit
www.mannkindcorp.com.
Forward-Looking StatementsThis press release
contains forward-looking statements that involve risks and
uncertainties. Words such as "believes," "anticipates," "plans,"
"expects," "intends," "will," "goal," "potential" and similar
expressions are intended to identify forward-looking statements.
These forward-looking statements are based upon MannKind's current
expectations. Actual results and the timing of events could differ
materially from those anticipated in such forward-looking
statements as a result of various risks and uncertainties detailed
in MannKind's filings with the SEC. For a discussion of these and
other factors, please refer to MannKind’s quarterly report on Form
10-Q for the quarter ended June 30, 2019 as well as MannKind’s
other filings with the SEC. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date of this press release. All forward-looking statements
are qualified in their entirety by this cautionary statement, and
MannKind undertakes no obligation to revise or update any
forward-looking statements to reflect events or circumstances after
the date of this press release.
MannKind Contact: Rose Alinaya Investor
Relations 818-661-5000 ir@mannkindcorp.com
Appendix – Presentation Information (1) Oral
Presentation: Technosphere Insulin Provides Better Early
Postprandial Glucose Control than Subcutaneous Rapid-Acting Analog
Presenter: David M. Kendall, M.D. Presentation No: 183Date/Time:
Thursday, September 19, 2019; 2:30 PM
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Aug 2024 to Sep 2024
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Sep 2023 to Sep 2024